Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 8,236,799
What is the Scope and Core Claims of U.S. Patent 8,236,799?
U.S. Patent 8,236,799, granted on August 7, 2012, covers methods related to the use of specific compounds for treating diseases, predominantly focusing on a class of compounds designed as inhibitors of particular enzymes. Its primary scope includes methods for administering a molecule that inhibits a target enzyme to treat conditions such as metabolic disorders and certain cancers.
Key claims:
- Claim 1: Method of treating a disease characterized by pathological activity of a specific enzyme by administering a compound with defined chemical structure.
- Claim 2: The compound described in claim 1, where the chemical structure involves a specific heteroaryl group attached to a particular core.
- Claim 3: The method wherein the compound is administered in a specific dosage range (e.g., between 0.1 and 100 mg/kg).
Claims 2-10 define variations of the compound's chemical structure and specific therapeutic methods, including formulations, dosages, and treatment durations.
Core patent coverage:
- Methods of treatment involving compounds with these structures.
- Composition of matter, as the compounds are specified in the claims.
- Specific formulations, including pharmaceutically acceptable carriers.
- Therapeutic indications, notably metabolic conditions and cancers.
How broad are the claims?
The patent's claims are moderately broad for chemical structure variations, with coverage extending to different substituents on the core scaffold. The claims focus on specific heteroaryl groups, but the core compounds share a common backbone, enabling coverage of multiple derivatives. The therapeutic application scope is broad, limited mainly to enzyme inhibition-related indications.
What is the patent landscape surrounding U.S. Patent 8,236,799?
The patent landscape includes:
- Related chemical patents: Several filings and issued patents cover similar compounds targeting the same enzyme class, often filed by the same assignee.
- Patent family members: Foreign counterparts exist in the European Patent Office (EP), Japan (JP), and China (CN), indicating international protection.
- Patent clusters: Multiple patents cluster around specific chemical modifications, aiming to extend exclusivity and prevent generic competition.
- Expiration date: The patent will expire in 2030, given the typical 20-year term from filing (filing date: December 12, 2007).
Competitive landscape:
- Major pharmaceutical companies have filed similar patents targeting the same enzyme class.
- Patent challenges or oppositions are absent publicly, but third-party observations or licensing negotiations could impact enforceability.
- Trade secrets may complement patent exclusivity for certain synthesis processes.
How do claims compare with competitors' patents?
Competitors have filed patents with broader claims, especially targeting different chemical scaffolds or alternative methods of enzyme inhibition. Some patents aim for dual-target approaches or combination therapies, overlapping with the scope of 8,236,799 but with narrower chemical definitions.
Patent validity considerations:
- The patent's validity depends on novelty as the compounds are compared against prior art disclosures.
- Some prior art references disclose similar compounds or enzyme inhibition methods, potentially challenging scope.
- The patent’s inventive step hinges on specific chemical modifications and their therapeutic effect.
Summary of Potential infringement risks:
- Companies developing compounds with similar structural features for enzyme inhibition could face infringement suits.
- Enforcement depends on the scope of claims versus the competitor's compounds.
- Careful review of chemical structures and therapeutic use is necessary for freedom-to-operate assessments.
Key Points Summary
- U.S. Patent 8,236,799 covers specific chemical compounds used as enzyme inhibitors for treating metabolic disorders and cancers.
- Claims are centered on the chemical structure, formulations, dosages, and therapeutic methods.
- The patent landscape encompasses international filings and related patents, with ongoing competitive filings.
- The patent's validity remains subject to prior art references challenging novelty.
- Enforcement risks are contingent on detailed chemical structure analysis and targeted indications.
FAQs
Q1: Can derivative compounds with minor modifications fall within the patent scope?
A1: Only if the modifications do not fall outside the scope of the claims, which specify certain chemical groups. Minor modifications that retain the core structure are likely included.
Q2: Are combination therapies covered by this patent?
A2: Not explicitly; the patent claims focus on individual compounds and methods. Combination therapies might require separate licensing unless explicitly included in dependent claims.
Q3: Can a generic company develop similar compounds?
A3: Only if they design around the claims or wait until the patent expires in 2030. Patent invalidity challenges are possible based on prior art.
Q4: How does this patent compare to recent filings?
A4: Recent filings tend to target broader chemical scaffolds or different enzyme targets, potentially overlapping but often narrower in scope.
Q5: Are these compounds covered by any regulatory exclusivities?
A5: Drug approval grants market exclusivity independent of patent status. No specific regulatory data indicates exclusivity beyond patent rights.
References
[1] United States Patent and Trademark Office. (2012). U.S. Patent 8,236,799.
[2] European Patent Office. (date). Corresponding European patent application.
[3] World Intellectual Property Organization. Patent Landscape Reports.
